CHCarroll M. Harmon

Carroll M. Harmon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carroll M. Harmon has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Min Chen

    Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, AL 35233, USA

    5 shared publications
  • Tara Jean Loux

    Department of Surgery, University of Alabama at Birmingham, Birmingham, USA

    3 shared publications
  • Charles J. Aprahamian

    Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, AL 35233, USA

    2 shared publications
  • Keith E. Georgeson

    Division of Pediatric Surgery, University of Alabama at Birmingham, Birmingham, AL 35233, USA

    2 shared publications
  • Ying-Kui Yang

    Department of Surgery, Division of Pediatric Surgery ACC 300, University of Alabama at Birmingham, Birmingham, USA

    2 shared publications
  • Yingkui Yang

    Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, AL 35233, USA

    2 shared publications

Latest Publications

  • Smaller scars—what is the big deal: a survey of the perceived value of laparoscopic pyloromyotomy

    by Ramanath N. Haricharan, Charles J. Aprahamian, Traci L. Morgan, Carroll M. Harmon, Keith E. Georgeson, Douglas C. Barnhart


  • Regulation of FAT/CD36 mRNA gene expression by long chain fatty acids in the differentiated 3T3-L1 cells

    by Yingkui Yang, Min Chen, Tara J. Loux, Carroll M. Harmon

    Defects in fatty acid translocase (FAT/CD36) have been identified as a major factor in insulin resistance and defective fatty acid and glucose metabolism. Therefore, understanding of the regulation of FAT/CD36 expression and function is important for a potential therapeutic target for type II diabetes. We differentiated 3T3-L1 preadipocytes into matured adipocytes and examined the roles of insulin and long chain fatty acids on FAT/CD36 expression and function. Our results indicate that FAT/CD36 mRNA expression was not detected at preadipocyte but was significantly increased at matured adipocyte. In fully differentiated 3T3-L1 adipocytes, insulin significantly increased FAT/CD36 mRNA and protein expression in a dose dependent manner. The free fatty acid stearic acid reduced FAT/CD36 mRNA expression while the non-metabolizable free fatty acid alpha-bromopalmitate (2-BP) significantly increased FAT/CD36 mRNA and protein expression. Isoproterenol, in contrast, dose-dependently reduced FAT/CD36 mRNA expression and increased free fatty acid release. Mechanism analysis indicated that the effect of insulin and 2-BP on the FAT/CD36 mRNA gene expression may be mediated through activation of PPAR-γ, suggesting that FAT/CD36 may have important implications in the pathophysiology of defective fatty acid metabolism.


  • A rat model of childhood diet-induced obesity: Roux-en-Y gastric bypass induced changes in metabolic parameters and gastric peptide ghrelin

    by Charles J. Aprahamian, Gonça Tekant, Min Chen, Ayden Yagmurlu, Ying-Kui Yang, Tara Loux, Carroll M. Harmon

    Childhood morbid obesity is reaching epidemic proportions. Roux-en-Y gastric bypass (RYGB) results in many metabolic alterations, including changes in glucose and lipid metabolism, and changes in levels of the gastric hormone, ghrelin. As more children are undergoing RYGB, an animal model would be beneficial to further study RYGB and its subsequent metabolic effects. DIO Sprague Dawley rats underwent RYGB, sham jejunojejunostomy (SH), or no operation (HFC) after 6 weeks of high-fat diet. Non-obese rats fed standard chow (SC) were a final control group. Animals were post-operatively fed standard chow for 7 days before sacrifice. At sacrifice, venous blood and gastric mucosa was collected for metabolic parameters and ghrelin determination. RYGB rats weighed less than SH and HFC (361 ± 8.8 vs. 437 ± 9.3 and 443 ± 6.2 g, P < 0.05). Compared to HFC, RYGB animals had decreased plasma glucose (292 ± 23 vs. 141 ± 10 mg/dL), cholesterol (80 ± 12 vs. 45 ± 5 mg/dL), triglycerides (138 ± 37 vs. 52 ± 7 mg/dL), HDL (43 ± 5 vs. 20 ± 3 mg/dL), and free fatty acids (0.72 ± 0.14 vs. 0.23 ± 0.02 mEq/L), all P < 0.05. Plasma ghrelin increased in RYGB rats compared to SC and HFC (116.22 ± 32.27 vs. 31.60 ± 2.66 and 31.75 ± 0.75 pg/mL, P < 0.05). In a rat model of RYGB, we demonstrated improved metabolic parameters and increased plasma and gastric mRNA ghrelin levels. The rat model for RYBG appears to be a reasonable model for future study of the cellular and molecular regulatory pathways of obesity and its surgical treatment.


  • The role of hyperglycemia in FAT/CD36 expression and function

    by Min Chen, Ying-Kui Yang, Tara J. Loux, Keith E. Georgeson, Carroll M. Harmon

    FAT/CD36 is a long-chain fatty acid transporter and scavenger receptor for oxidized LDL. Defects in FAT/CD36 have been linked to the hypertriglyceridemia and insulin resistance. Expression of FAT/CD36 was reported increase in type 1 diabetes; however, it remains unclear whether serum glucose or insulin plays an important role in this regulation. To elucidate the individual contribution of plasma glucose and insulin in the regulation of FAT/CD36 mRNA expression, we induced type 1 diabetes in male Sprague-Dawley rats using streptozotocin (STZ) and compared traditional insulin treatment with administration of the orally absorbed chemical agent vanadate, which reduces blood glucose levels via mechanisms that bypass insulin receptor action. STZ-exposed animals showed significant decreases in body weight (285.5 ± 2.8 vs. 233.1 ± 3.5 g, P < 0.001) and serum insulin levels (9.7 ± 0.7 vs. 2.8 ± 0.6 μU/ml, P < 0.05), accompanied by significant increases in blood glucose (71 ± 3 vs. 433 ± 11 mg/dl, P < 0.001), water intake (38.9 ± 0.9 vs. 205.9 ± 3.3 ml/day, P < 0.001) and food intake (22.0 ± 0.4 vs. 36.9 ± 1.0 g/day, P < 0.001). Diabetic animals demonstrated significant increases in FAT/CD36 mRNA levels in duodenum (2.2-fold), jejunum (1.8-fold), ileum (1.5-fold), adipose tissue (1.7-fold), and heart (2.5-fold) (P < 0.05). Insulin treatment reversed body weight loss and corrected hyperglycemia at diabetic rats as expected. Insulin treatment also corrected increased FAT/CD36 mRNA expression at diabetic rats. Vanadate significantly reduced serum glucose levels without increasing serum insulin or affecting body weight but reversed increased FAT/CD36 mRNA expression in diabetic rats. These data suggest that plasma glucose levels play more important role in the regulation of FAT/CD36 expression than concurrent changes in plasma insulin.


  • Laparoscopic cecostomy button placement for the management of fecal incontinence in children with Hirschsprung’s disease and anorectal anomalies

    by A. Yagmurlu, C. M. Harmon, K. E. Georgeson

    Antegrade colonic enemas offer a surgical solution for many children with chronic constipation and encopresis associated with Hirschsprung’s disease and anorectal malformations. This study demonstrated the feasibility of a new laparoscopic technique for cecostomy button placement (LCBP) to allow antegrade enema treatment. Charts of children with encopresis who underwent LCBP between 1999 and 2001 were reviewed. The age, weight, primary diagnosis, operative time, hospital stay, associated complications, follow-up duration, and outcome of the patients were recorded. The surgical technique used a “U-stitch” method and a chait tube or a standard gastrostomy button. A follow-up telephone survey was conducted to assess parental satisfaction and overall success in continence. Seven patients ages 4 to 12 years (mean, 7.3 ± 1.3 years) and weighing 15 to 44 kg (mean, 24.5 ± 4 kg) underwent LCBP over a 2-year period. The mean follow-up period was 15 ± 4 months (range, 6–33 months). Four patients had anorectal malformations, and three patients had Hirschsprung’s disease. For all the patients, LCBP was accomplished without any intraoperative complications. The mean operative time was 33 ± 2 min, and the hospital stay was 2 to 5 days (mean, 3.8 ± 0.5 days). The patients received one or two daily antegrade enemas, and none had accidental bowel movements. Episodes of soiling at night once or twice a week were observed with two children. Two patients had hypertrophic granulation tissue formation, which responded to topical therapy. The button was uneventfully changed twice in one patient because of mechanical malfunction. To manage overflow incontinence of children with anorectal malformations and Hirschsprung’s disease, LCBP is a technically straightforward, effective, and reversible method for the placement of a cecostomy button.


  • Total parenteral nutrition alters enterocyte fatty acid translocase / CD36 expression

    by Min Chen, Daniel H. Teitelbaum, Hua Yang, Carroll M. Harmon